Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Mark Bartlett who wrote (1686)	4/21/1999 7:21:00 AM
From: Mark Bartlett	Respond to of 14101

Tom, Looks like I was a little hasty in the last post .... it appears that diclofenac at 6 months caused more ulcers than Celebrex - that being said, it goes on to say: "The correlation between findings of endoscopic studies, and the relative incidence of clinically serious upper GI events that may be observed with different products, has not been fully established. Serious clinically significant upper GI bleeding has been observed in patients receiving Celebrex in controlled and open-labeled trials, albeit infrequently (see WARNINGS — Gastrointestinal [GI] effects). Prospective, long-term studies required to compare the incidence of serious, clinically significant upper GI adverse events in patients taking Celebrex vs. comparator NSAID products have not been performed." MB